This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Acutus Medical, Inc. (AFIB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -3.28% and 14.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will High Medical Costs Hurt Cigna (CI) in Q2 Earnings?
by Zacks Equity Research
Cigna's (CI) Q2 results are likely to reflect strength in the specialty pharmacy business and growing medical customer base, partly offset by higher medical expenses.
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 23.38% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Jazz Pharmaceuticals, Oshkosh and StoneCo
by Zacks Equity Research
Jazz Pharmaceuticals, Oshkosh and StoneCo are part of the Zacks top Analyst Blog.
3 Stocks to Buy as Recession Looks Unlikely
by Sejuti Banerjea
These are opportunities to buy at reasonable valuations.
Jazz Pharmaceuticals (JAZZ) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Growing Customer Base Aid Centene (CNC) in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) Q2 results are likely to reflect growing Medicaid and Marketplace membership, coupled with an improved HBR, partly offset by escalating medical expenses.
What's in the Cards for Universal Health (UHS) in Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.
Will High Medical Costs Hurt Molina Healthcare's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q2 results are likely to reflect the membership growth in its Medicaid and Medicare business units, partly offset by an elevated medical cost level.
Will High Tech Costs Hurt Teladoc Health (TDOC) in Q2 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) Q2 results are likely to have benefited from improved access fees and growing BetterHelp membership, partly offset by elevated technology and development expenses.